NCT03174197View on ClinicalTrials.gov

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

September 17, 2025

Study Completion Date

September 17, 2025

Conditions

GlioblastomaGliosarcoma

Interventions

DRUG

Atezolizumab

Given IV

RADIATION

Radiation Therapy

Undergo RT

DRUG

Temozolomide

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03174197 - Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter